MIDODRINE HYDROCHLORIDE | A076577 | MYLAN PHARMACEUTICALS INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Haynes and Boone, LLP FDA-2018-P-1698 · 7 docket documents Haynes and Boone, LLP filed this citizen petition under Section 505(j)(2)(C) requesting that the FDA determine Midodrine Hydrochloride Oral Solution, 2.5 mg/5 ml, is suitable for submission in an ANDA, with Mylan's Midodrine Hydrochloride Oral Tablets, 5 mg, as the reference listed drug. The petitio | Suitability | 2018-05-02 | Open | Haynes and Boone, LLP |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1469
per ea
Lowest NADAC/Unit
$0.0717
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00378190301MIDODRINE HCL 10 MG TABLET | $0.1469 | EA | Generic | — | 2026-06-17 |
| 00378190201MIDODRINE HCL 5 MG TABLET | $0.1112 | EA | Generic | — | 2026-06-17 |
| 51079045320MIDODRINE HCL 5 MG TABLET | $0.1112 | EA | Generic | — | 2026-06-17 |
| 00378190101MIDODRINE HCL 2.5 MG TABLET | $0.0717 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.